JB Pharma reports significant ESG progress, high score in S&P assessment

J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) announced its fourth Sustainability (ESG) Report for the financial year 2024-25, showcasing significant improvements across its operations. The company achieved an ESG score of 77 in the S&P Global Corporate Sustainability Assessment (DJSI), marking an 87% improvement from the previous year. Key environmental achievements include a more than 34% decrease in Scope 1 emissions, a more than 14% decrease in NOx, SOx, and PM, and a more than 6% reduction in groundwater consumption. Renewable energy sources met over 37% of the total energy demand, with consumption increasing by more than 273% year-on-year.

In social performance, JB Pharma reported zero cases of injuries, fatalities, or occupational diseases and conducted a Human Rights Assessment for all internal stakeholders. The company also positively impacted lives through its corporate social responsibility (CSR) initiatives, spending approximately Rs. 11.23 crores on projects in designated aspirational districts. Governance highlights include an achieved score of 80 in the Governance & Economic Dimension and zero cases pertaining to conflicts of interest among directors.

JB Pharma aims for carbon neutrality in direct operations by fiscal year 2032-33 and seeks to achieve 100% renewable energy for its power needs by the same year. The company is committed to zero waste to landfill by fiscal year 2032-33 and plans to increase female representation in its total workforce to 15% by fiscal year 2026-27.